Literature DB >> 10381492

The C282Y mutation causing hereditary hemochromatosis does not produce a null allele.

J E Levy1, L K Montross, D E Cohen, M D Fleming, N C Andrews.   

Abstract

Targeted mutagenesis was used to produce two mutations in the murine hemochromatosis gene (Hfe) locus. The first mutation deletes a large portion of the coding sequence, generating a null allele. The second mutation introduces a missense mutation (C282Y) into the Hfe locus, but otherwise leaves the gene intact. This mutation is identical to the disease-causing mutation in patients with hereditary hemochromatosis. Mice carrying each of the two mutations were bred and analyzed. Homozygosity for either mutation results in postnatal iron loading. The effects of the null mutation are more severe than the effects of the C282Y mutation. Mice heterozygous for either mutation accumulate more iron than normal controls. Interestingly, although liver iron stores are greatly increased, splenic iron is decreased. We conclude that the C282Y mutation does not result in a null allele.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381492

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  74 in total

1.  The haemochromatosis protein HFE induces an apparent iron-deficient phenotype in H1299 cells that is not corrected by co-expression of beta 2-microglobulin.

Authors:  Jian Wang; Guohua Chen; Kostas Pantopoulos
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

2.  Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice.

Authors:  G Nicolas; M Bennoun; I Devaux; C Beaumont; B Grandchamp; A Kahn; S Vaulont
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice.

Authors:  Junwei Gao; Juxing Chen; Ivana De Domenico; David M Koeller; Cary O Harding; Robert E Fleming; Dwight D Koeberl; Caroline A Enns
Journal:  Blood       Date:  2010-02-22       Impact factor: 22.113

4.  Regulation of lipopolysaccharide-induced translation of tumor necrosis factor-alpha by the toll-like receptor 4 adaptor protein TRAM.

Authors:  Lijian Wang; Estela Trebicka; Ying Fu; Lisa Waggoner; Shizuo Akira; Katherine A Fitzgerald; Jonathan C Kagan; Bobby J Cherayil
Journal:  J Innate Immun       Date:  2011-04-14       Impact factor: 7.349

Review 5.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

6.  Of mice and men: the iron age.

Authors:  Sophie Vaulont; Dan-Qing Lou; Lydie Viatte; Axel Kahn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  A mouse model of juvenile hemochromatosis.

Authors:  Franklin W Huang; Jack L Pinkus; Geraldine S Pinkus; Mark D Fleming; Nancy C Andrews
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 8.  Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?

Authors:  Duygu Dee Harrison-Findik
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

9.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 10.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.